TY - JOUR
T1 - Effects of menatetrenone on the bone and serum levels of vitamin K2 (menaquinone derivatives) in osteopenia induced by phenytoin in growing rats
AU - Onodera, Kenji
AU - Takahashi, Atsushi
AU - Wakabayashi, Hiroyuki
AU - Kamei, Jyunzo
AU - Sakurada, Shinobu
N1 - Funding Information:
This study was supported in part by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology in Japan (12671796 to K.O.).
PY - 2003/5/1
Y1 - 2003/5/1
N2 - OBJECTIVE: We investigated the effects of phenytoin, an antiepileptic drug, and vitamin K2 (menatetrenone) on bone mineral density and the changes in the levels of menaquinone derivatives (MK-1 ∼ MK-14) in the sera and femurs of growing male rats. METHODS: Levels of menaquinone derivatives were measured with high-performance liquid chromatography with an electrochemical detector. RESULTS: Bone mineral density values decreased significantly in all parts of the femoral bones measured (diaphysis and metaphysis) in the phenytoin-treated group. When the serum and bone levels of menatetrenone and MK-6 decreased due to phenytoin administration, we observed bone loss in rats. Conversely, when bone loss was prevented by the combined administration of phenytoin and menatetrenone, serum and bone levels of menatetrenone and MK-6 increased to the levels of vehicle-treated rats. CONCLUSIONS: Long-term phenytoin exposure may inhibit bone formation concomitantly with insufficient vitamin K, which, at least in part, contributes to bone loss in rats.
AB - OBJECTIVE: We investigated the effects of phenytoin, an antiepileptic drug, and vitamin K2 (menatetrenone) on bone mineral density and the changes in the levels of menaquinone derivatives (MK-1 ∼ MK-14) in the sera and femurs of growing male rats. METHODS: Levels of menaquinone derivatives were measured with high-performance liquid chromatography with an electrochemical detector. RESULTS: Bone mineral density values decreased significantly in all parts of the femoral bones measured (diaphysis and metaphysis) in the phenytoin-treated group. When the serum and bone levels of menatetrenone and MK-6 decreased due to phenytoin administration, we observed bone loss in rats. Conversely, when bone loss was prevented by the combined administration of phenytoin and menatetrenone, serum and bone levels of menatetrenone and MK-6 increased to the levels of vehicle-treated rats. CONCLUSIONS: Long-term phenytoin exposure may inhibit bone formation concomitantly with insufficient vitamin K, which, at least in part, contributes to bone loss in rats.
KW - High-performance liquid chromatography and electrochemical detector
KW - Menatetrenone
KW - Osteopenia
KW - Phenytoin
KW - Vitamin K
UR - http://www.scopus.com/inward/record.url?scp=0037404098&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037404098&partnerID=8YFLogxK
U2 - 10.1016/S0899-9007(02)00962-0
DO - 10.1016/S0899-9007(02)00962-0
M3 - Article
C2 - 12714099
AN - SCOPUS:0037404098
VL - 19
SP - 446
EP - 450
JO - Nutrition
JF - Nutrition
SN - 0899-9007
IS - 5
ER -
